(Reuters) -Biogen expects growth of its keenly watched Alzheimer’s disease drug, Leqembi, to see a “linear trend” in the United States in the near term, a company executive said at a healthcare conference on Tuesday. The drugmaker has been navigating the slow pick-up of Leqembi in the United States, amid concerns over cost, efficacy and […]
Health
Biogen expects steady growth for Alzheimer’s drug Leqembi in near term
Audio By Carbonatix
(Reuters) -Biogen expects growth of its keenly watched Alzheimer’s disease drug, Leqembi, to see a “linear trend” in the United States in the near term, a company executive said at a healthcare conference on Tuesday.
The drugmaker has been navigating the slow pick-up of Leqembi in the United States, amid concerns over cost, efficacy and side effects.
“I would expect a linear trend…at this point, until some things sort of change in the market,” Alisha Alaimo, Biogen’s head of North America, said at the Evercore HealthCONx Conference.
Leqembi, which Biogen sells with partner Eisai, brought in about $39 million in U.S. sales in the third quarter, up about $9 million from the previous quarter.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)